Craig Gibbs, Asher Biotherapeutics CEO (Asher)
A next-gen IL-2 challenger bags a megaround with RA Capital on board to accelerate 'modular' drug platform
Cracking the IL-2 puzzle box has been a point of contention in biotech for years as drug developers look to beat a slate of serious …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.